James R. Gavin III, MD, PhD

AI in diabetes care is becoming more popular with various potential benefits for patients and clinicians as well as important challenges to keep in mind, according to a conversation between two diabetes experts.

ORLANDO — In this video exclusive, James R. Gavin III, MD, PhD, Healio | Endocrine Today co-editor, talks with Edward C. Chao, DO, about the importance of not worsening disparities with the implementation of AI in diabetes care.

ORLANDO — In this video exclusive, James R. Gavin III, MD, PhD, Healio | Endocrine Today co-editor, talks with Edward C. Chao, DO, about important considerations for using AI in clinical practice.

ORLANDO — In this video exclusive, James R. Gavin III, MD, PhD, Healio | Endocrine Today co-editor, talks with Edward C. Chao, DO, about the benefits and challenges of using AI in diabetes care.

Continuous glucose monitors have the potential to alleviate burdens, improve neonatal outcomes and predict disease progression for pregnant women with type 1, type 2 or gestational diabetes, according to two diabetes experts.

Among adults with type 2 diabetes, white men and white women and those seeing an endocrinologist receive more prescriptions for SGLT2 inhibitors and GLP-1 receptor agonists than Black adults and those seen only in primary care, data show.

NEW ORLEANS — In part 2 of this video exclusive, James R. Gavin III, MD, PhD, talks with Anne L. Peters, MD, about a nonprofit model for expanding access to diabetes care.

NEW ORLEANS — In the third part of this video exclusive, James R. Gavin III, MD, PhD, talks with Jamy D. Ard, MD, about new drugs for substantial weight loss and treatment of obesity-related comorbidities, including type 2 diabetes and liver disease.

NEW ORLEANS — In this video exclusive, James R. Gavin III, MD, PhD, talks with Jamy D. Ard, MD, about the misleading concept of metabolically healthy obesity, its effect of delaying early treatment and the benefit of small weight losses.

NEW ORLEANS— In part one of this video exclusive, James R. Gavin III, MD, PhD, talks with Anne L. Peters, MD, about using technology in underserved populations to close the diabetes treatment gap.